Aarti Pharmalabs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 22, 2025
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs Limited submitted the Scrutinizer's Report and voting results for its 6th AGM held on September 22, 2025, conducted via Video Conferencing. Shareholders passed all 8 resolutions with the requisite majority, with about 82 shareholders (11 promoter group, 71 public) attending through VC. Key approvals include adoption of FY25 audited financial statements (98.53% in favour), final dividend for FY24-25 (99.996% in favour), re-appointment of Parimal H. Desai and Independent Director Rupal Vora, ratification of Cost Auditor remuneration, appointment of Secretarial Auditor for 5 years, revision in MD Narendra Salvi's remuneration (99.96% in favour), and extension of ESOP benefits to subsidiary employees (87.66% in favour). The lowest support came from public institutional investors on Resolutions 3 (72.43% against Parimal Desai's reappointment) and 8 (59.58% against ESOP extension to subsidiaries), though both still passed overall.
All resolutions were approved, including the final dividend for FY24-25, which is a positive confirmation for shareholders. No material corporate action or governance issue arises from the vote outcomes, and the stock is unlikely to see significant price movement purely on this disclosure.